Literature DB >> 24225075

Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a retrospective study on 126 patients.

Lan-Huong Thai1, Pierre Charles1, Matthieu Resche-Rigon2, Kristell Desseaux2, Loïc Guillevin3.   

Abstract

OBJECTIVES: Predicting granulomatosis with polyangiitis (Wegener's) (GPA) relapses based on ANCA titers remains a source of debate. Our objective was to evaluate the relevance of monitoring PR3-ANCA titers for GPA management.
METHODS: This retrospective study included 126 patients fulfilling the 1990 ACR criteria for GPA and PR3-ANCA-positive at the time of diagnosis. Disease activity was assessed with BVAS/WG and Disease Extent Index. For each patient, a median of 12 serum samples was analyzed, i.e., one every 5.5months.
RESULTS: Induction therapy obtained remission in 88% of the patients. ANCA became negative by IF for 70/115 (60.9%) patients and by ELISA for 90/115 (78.3%). After median follow-up of 70months, 85/126 (67.5%) patients had 154 clinical relapses associated with cANCA and PR3-ANCA-positivity for 122 (79.2%) and 102 (66.2%) of them, respectively. Relapse-free survival was significantly longer for patients who remained PR3-ANCA-negative (HR 0.60 [95% CI 0.39-0.92], P=0.02). Individual ANCA-profile analysis revealed that, for 60% of GPA patients, clinical outcomes and ANCA-titer changes were closely associated, i.e., ANCA were always positive during relapses and negative during remission. The 35 patients with fluctuating ANCA-positivity during remission were in partial remission or had developed grumbling GPA.
CONCLUSION: Although ANCA were positive during most systemic relapses or residual disease, no strict clinical-immunological correspondence was observed for 25% of the patients. Thus, GPA management cannot be based on ANCA levels alone.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ANCA; Disease activity; Granulomatosis with polyangiitis (Wegener's); Monitoring; Proteinase 3; Relapse

Mesh:

Substances:

Year:  2013        PMID: 24225075     DOI: 10.1016/j.autrev.2013.11.003

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  22 in total

Review 1.  Vasculitis for the internist: focus on ANCA-associated vasculitis.

Authors:  Benjamin Chaigne; Loïc Guillevin
Journal:  Intern Emerg Med       Date:  2017-06-16       Impact factor: 3.397

Review 2.  Interleukin-9 and T helper type 9 cells in rheumatic diseases.

Authors:  F Ciccia; G Guggino; A Ferrante; P Cipriani; R Giacomelli; G Triolo
Journal:  Clin Exp Immunol       Date:  2016-08       Impact factor: 4.330

3.  Antineutrophil cytoplasmic antibodies and their relationship with disease activity and presence of staphylococcal superantigens in nasal swabs in patients having granulomatosis with polyangiitis: results of a study involving 115 patients from a single center.

Authors:  Justyna Fijolek; E Wiatr; V Petroniec; E Augustynowicz-Kopec; M Bednarek; D Gawryluk; K Roszkowski-Sliz
Journal:  Clin Rheumatol       Date:  2019-07-23       Impact factor: 2.980

4.  ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease.

Authors:  Michael J Kemna; Jan Damoiseaux; Jos Austen; Bjorn Winkens; Jim Peters; Pieter van Paassen; Jan Willem Cohen Tervaert
Journal:  J Am Soc Nephrol       Date:  2014-10-16       Impact factor: 10.121

Review 5.  Biomarkers in ANCA-Associated Vasculitis: Potential Pitfalls and Future Prospects.

Authors:  Adam D Morris; Anthony W Rowbottom; Francis L Martin; Alexander Woywodt; Ajay P Dhaygude
Journal:  Kidney360       Date:  2021-01-19

6.  The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study.

Authors:  Gregory McDermott; Xiaoqing Fu; Claire Cook; Catherine Ahola; Brett Doliner; Jennifer Hanberg; John H Stone; Hyon K Choi; Yuqing Zhang; Zachary S Wallace
Journal:  Ann Rheum Dis       Date:  2022-06-13       Impact factor: 27.973

Review 7.  B cell-mediated pathogenesis of ANCA-mediated vasculitis.

Authors:  J Charles Jennette; Ronald J Falk
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

Review 8.  Autoimmunity in 2014.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

9.  Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.

Authors:  Lynn A Fussner; Amber M Hummel; Darrell R Schroeder; Francisco Silva; Rodrigo Cartin-Ceba; Melissa R Snyder; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; Nadia K Tchao; John H Stone; Ulrich Specks
Journal:  Arthritis Rheumatol       Date:  2016-07       Impact factor: 10.995

10.  Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited.

Authors:  Amina Bensalem; Denis Mulleman; Gilles Paintaud; Nicolas Azzopardi; Valérie Gouilleux-Gruart; Divi Cornec; Ulrich Specks; David Ternant
Journal:  Clin Pharmacokinet       Date:  2020-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.